A new generation M(pro) inhibitor with potent activity against SARS-CoV-2 Omicron variants

Emerging SARS-CoV-2 variants, particularly the Omicron variant and its sublineages, continually threaten the global public health. Small molecule antivirals are an effective treatment strategy to fight against the virus. However, the first-generation antivirals either show limited clinical efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chong, Shuai, Huiping, Qiao, Jingxin, Hou, Yuxin, Zeng, Rui, Xia, Anjie, Xie, Lingwan, Fang, Zhen, Li, Yueyue, Yoon, Chaemin, Huang, Qiao, Hu, Bingjie, You, Jing, Quan, Baoxue, Zhao, Xiu, Guo, Nihong, Zhang, Shiyu, Ma, Ronggang, Zhang, Jiahao, Wang, Yifei, Yang, Ruicheng, Zhang, Shanshan, Nan, Jinshan, Xu, Haixing, Wang, Falu, Lei, Jian, Chu, Hin, Yang, Shengyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018608/
https://www.ncbi.nlm.nih.gov/pubmed/36928316
http://dx.doi.org/10.1038/s41392-023-01392-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018608/
https://www.ncbi.nlm.nih.gov/pubmed/36928316
http://dx.doi.org/10.1038/s41392-023-01392-w

Ejemplares similares